Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F. Kelley, Renu Singh, Carlos Brites et al.|New England Journal of Medicine|2024Cited by 260
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trialSamir K. Gupta, Ellen Koenig, Mezgebe Berhe et al.|The Lancet HIV|2022Cited by 107
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trialOnyema Ogbuagu, Hui Wang, Nicolas Margot et al.|The Lancet HIV|2023Cited by 71
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyJoseph J. Eron, Marina Caskey, Susan J. Little et al.|The Lancet HIV|2024Cited by 47